Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Authors
Andrew Roberts•Lori Gressick•John Seymour
Journal
New England Journal of Medicine
Published
December 6, 2015
Abstract
New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.